Epix testing MS-325 for cardiac imaging

MR contrast agent developer Epix Medical has begun a multicenter phase IIa clinical trial of its MS-325 blood-pool contrast agent for imaging both the coronary arteries and myocardial perfusion.

The goal of the study is to assess the feasibility of using MS-325-enhanced MR angiography for coronary angiography and cardiac perfusion imaging, according to the Cambridge, MA-based firm.

By AuntMinnie.com staff writers
July 12, 2004

Related Reading

Epix launches new MS-325 trial, July 8, 2004

Schering submits MS-325 for EU approval, June 7, 2004

Epix raises $96 million, June 4, 2004

Epix floats new debt, June 2, 2004

Copyright © 2004 AuntMinnie.com

Page 1 of 606
Next Page